AZD6738 Inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1/P53 and PI3K/AKT pathways
Longxiang Huang et al, 2022, Frontiers in Pharmacology CrossRef
Isovalerylspiramycin I suppresses small cell lung cancer proliferation via ATR/CHK1 mediated DNA damage response and PERK/eIF2α/ATF4/CHOP mediated ER stress
Yongle Xu et al, 2024, Biochemical Pharmacology CrossRef
The Unique Pt(II)-Induced Nucleolar Stress Response and its Deviation from DNA Damage Response Pathways
Hannah C. Pigg et al, 2024, Journal of Biological Chemistry CrossRef
The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy
Frank P. Vendetti et al, 2023, JCI Insight CrossRef
Update on Emerging Therapies for Advanced Colorectal Cancer
Olatunji B. Alese et al, 2023, American Society of Clinical Oncology Educational Book CrossRef
AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells
Shinnosuke Harata et al, 2023, Oncology Reports CrossRef
MFAE: Multilevel Feature Aggregation Enhanced Drug‐Target Affinity Prediction for Drug Repurposing Against Colorectal Cancer
Guanxing Chen et al, 2024, Advanced Intelligent Systems CrossRef
Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells
Yoshihito Morimoto et al, 2024, Cancer Chemotherapy and Pharmacology CrossRef
ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells
Zijie Gao et al, 2022, Journal of Experimental & Clinical Cancer Research CrossRef
Short-Course But Not Prolonged Treatment With ATR Inhibitor AZD6738 Integrates With Radiotherapy to Generate a Tumor Antigen-Specific CD8 ⁺ T Cell Expansion in the Periphery
Frank P. Vendetti et al, SSRN Electronic Journal CrossRef
The Adaptive Mechanisms and Checkpoint Responses to a Stressed DNA Replication Fork
Joanne Saldanha et al, 2023, International Journal of Molecular Sciences CrossRef